These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7601569)

  • 1. Sequence specificity on the growth suppression and induction of apoptosis of chronic myeloid leukemia cells by BCR-ABL anti-sense oligodeoxynucleoside phosphorothioates.
    Maekawa T; Kimura S; Hirakawa K; Murakami A; Zon G; Abe T
    Int J Cancer; 1995 Jul; 62(1):63-9. PubMed ID: 7601569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of BCR-ABL antisense oligonucleotides (AS-ODN) on human chronic myeloid leukemic cells: AS-ODN as effective purging agents.
    Wu AG; Joshi SS; Chan WC; Iversen PL; Jackson JD; Kessinger A; Pirruccello SJ; Sanger WG; Sharp JG; Verbik DJ
    Leuk Lymphoma; 1995 Dec; 20(1-2):67-76. PubMed ID: 8750625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of chronic myelogenous leukemia cells harboring a BCR-ABL B3A2 junction by antisense oligonucleotides targeted at the B2A2 junction.
    Mahon FX; Ripoche J; Pigeonnier V; Jazwiec B; Pigneux A; Moreau JF; Reiffers J
    Exp Hematol; 1995 Dec; 23(14):1606-11. PubMed ID: 8542954
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphorothioate BCR-ABL antisense oligonucleotides induce cell death, but fail to reduce cellular bcr-abl protein levels.
    Smetsers TF; van de Locht LT; Pennings AH; Wessels HM; de Witte TM; Mensink EJ
    Leukemia; 1995 Jan; 9(1):118-30. PubMed ID: 7845006
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A comparison of the effect of bcr/abl breakpoint specific phosphothiorate oligodeoxynucleotides on colony formation by bcr/abl positive and negative, CD34 enriched mononuclear cell populations.
    Chasty R; Whetton A; Lucas G
    Leuk Res; 1996 May; 20(5):391-5. PubMed ID: 8683978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antisense BCR-ABL oligonucleotides induce apoptosis in the Philadelphia chromosome-positive cell line BV173.
    Smetsers TF; Skorski T; van de Locht LT; Wessels HM; Pennings AH; de Witte T; Calabretta B; Mensink EJ
    Leukemia; 1994 Jan; 8(1):129-40. PubMed ID: 8289478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of bcr-abl oligodeoxynucleotides on the clonogenic growth of chronic myelogenous leukaemia cells.
    de Fabritiis P; Skorski T; De Propris MS; Paggi MG; Nieborowska-Skorska M; Lisci A; Buffolino S; Campbell K; Geiser T; Calabretta B
    Leukemia; 1997 Jun; 11(6):811-9. PubMed ID: 9177433
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Specific antisense oligomer anti Bcr-abl junctions in chronic myeloid leukemia: a cell cycle analysis and CFU-GM study.
    Mahon FX; Belloc F; Vianes I; Barbot C; Boiron JM; Cowen D; Lacombe F; Brizard A; Bilhou-Nabera C; Bernard P
    Leuk Lymphoma; 1995 Nov; 19(5-6):423-9. PubMed ID: 8590842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poor cellular uptake of antisense oligodeoxynucleotides: an obstacle to their use in chronic myeloid leukaemia.
    Clark RE
    Leuk Lymphoma; 1995 Oct; 19(3-4):189-95. PubMed ID: 8535209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of BCR/ABL transcript variants with different blood parameters and demographic features in Iraqi chronic myeloid leukemia patients.
    Khazaal MS; Hamdan FB; Al-Mayah QS
    Mol Genet Genomic Med; 2019 Aug; 7(8):e809. PubMed ID: 31206255
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense BCR-ABL oligomers cause non-specific inhibition of chronic myeloid leukemia cell lines.
    O'Brien SG; Kirkland MA; Melo JV; Rao MH; Davidson RJ; McDonald C; Goldman JM
    Leukemia; 1994 Dec; 8(12):2156-62. PubMed ID: 7808004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Analysis of Bcr-abl type transcript and its relationship with platelet count in Mexican patients with chronic myeloid leukemia].
    Rosas-Cabral A; Martínez-Mancilla M; Ayala-Sánchez M; Vela-Ojeda J; Bahena-Reséndiz P; Vadillo-Buenfil M; Aviña-Zubieta JA; Salazar-Exaire D; Miranda-Peralta E; Marroquín A; Longoria-Revilla E
    Gac Med Mex; 2003; 139(6):553-9. PubMed ID: 14723051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving the intracellular delivery and molecular efficacy of antisense oligonucleotides in chronic myeloid leukemia cells: a comparison of streptolysin-O permeabilization, electroporation, and lipophilic conjugation.
    Spiller DG; Giles RV; Grzybowski J; Tidd DM; Clark RE
    Blood; 1998 Jun; 91(12):4738-46. PubMed ID: 9616172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of antisense oligodeoxynucleotide structure for targeting bcr-abl mRNA.
    Giles RV; Spiller DG; Green JA; Clark RE; Tidd DM
    Blood; 1995 Jul; 86(2):744-54. PubMed ID: 7606003
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia.
    Perego RA; Costantini M; Cornacchini G; Gargantini L; Bianchi C; Pungolino E; Rovida E; Morra E
    Eur J Cancer; 2000 Jul; 36(11):1395-401. PubMed ID: 10899653
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Unmodified phosphodiester antisense oligodeoxynucleotides to the BCR-ABL junction do not suppress Philadelphia-positive clonogenic cells.
    Käbisch A; Pérènyi L; Seay U; Lohmeyer J; Pralle H
    Acta Haematol; 1994; 92(4):190-6. PubMed ID: 7701917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrovirally transduced antisense sequences stably suppress P210BCR-ABL expression and inhibit the proliferation of BCR/ABL-containing cell lines.
    Martiat P; Lewalle P; Taj AS; Philippe M; Larondelle Y; Vaerman JL; Wildmann C; Goldman JM; Michaux JL
    Blood; 1993 Jan; 81(2):502-9. PubMed ID: 8422466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides.
    Skorski T; Nieborowska-Skorska M; Wlodarski P; Perrotti D; Hoser G; Kawiak J; Majewski M; Christensen L; Iozzo RV; Calabretta B
    J Natl Cancer Inst; 1997 Jan; 89(2):124-33. PubMed ID: 8998181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Frequency of BCR-ABL fusion transcripts in Sudanese patients with chronic myeloid leukemia using real-time reverse transcription-polymerase chain reaction.
    Muddathir AM; Kordofani AA; Fadl-Elmula IM
    Saudi Med J; 2013 Jan; 34(1):29-33. PubMed ID: 23299156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
    Haaß W; Kleiner H; Weiß C; Haferlach C; Schlegelberger B; Müller MC; Hehlmann R; Hofmann WK; Fabarius A; Seifarth W; ;
    PLoS One; 2015; 10(6):e0129648. PubMed ID: 26087013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.